Kisspeptin is a brain chemical that can turn on the reproductive hormone system and seems to boost activity in brain areas tied to sexual desire. Animal work shows it affects mating behavior differently in males and females, and early human scans suggest it may make the brain more responsive to sexual and emotional cues. Researchers think it could become a drug for low libido, but they still need to figure out the right doses, how to give it safely, and how it works differently in men and women.

The neuropeptide kisspeptin activates the hypothalamic-pituitary-gonadal (HPG) axis and influences neural circuits controlling sexual behavior. Animal studies have determined its sex-specific roles in reproductive behaviors, whereas human research has linked kisspeptin to increased brain activity in regions associated with sexual and emotional processing, making it a potential treatment for disorders of sexual desire. Here I discuss the current evidence on the promise of kisspeptin as a therapy for sexual dysfunction, highlight the challenges currently hindering its application, and advocate future studies focusing on sex-specific effects and interactions within the neuroendocrine system. Understanding its broader physiological roles and improving delivery methods will be key to unlocking kisspeptin's therapeutic potential.